Efficacy News and Research

RSS
Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

Denosumab increases bone density for postmenopausal women with osteoporosis

Denosumab increases bone density for postmenopausal women with osteoporosis

BPA appears to increase proliferation of breast cancer cells, diminish effectiveness of treatments

BPA appears to increase proliferation of breast cancer cells, diminish effectiveness of treatments

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

NCL collaborates with PeptiMed to evaluate safety and efficacy of nanocomplex materials

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Debiopharm launches Phase 1 study of anti-infective agent Debio 1450

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Western Oncolytics closes $275,000 in seed funding

Western Oncolytics closes $275,000 in seed funding

Study: E-cigarettes often advertised on Twitter

Study: E-cigarettes often advertised on Twitter

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Enhancing vaccine efficiency through encapsulation

Enhancing vaccine efficiency through encapsulation

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Lipids efficiently kill leukemia cells

Lipids efficiently kill leukemia cells

Scientists identify novel approach to treating multiple sclerosis

Scientists identify novel approach to treating multiple sclerosis

Survival differences after docetaxel, erlotinib are EGFR dependent

Survival differences after docetaxel, erlotinib are EGFR dependent

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.